Closed intravenous set for administering anticancer drug

Abstract

The present invention relates to a closed intravenous set for administering an anticancer drug. The intravenous set comprises a spike, a drip chamber, and a tube to guide a medicinal fluid stored in an intravenous bag to be administered to a patient, wherein the spike and the drip chamber are separated from each other, the spike has a first connecting member at the lower end thereof, and the drip chamber has a second connecting member at the upper end thereof, which is detachably connected to the first connecting member. According to the present invention, safety can be ensured without the risk of leakage of the anticancer drug or infection that may occur during administration.

Description

Closed IV set for anticancer drug administration

[0001] The present invention relates to an infusion set used when administering a drug to a patient, and more particularly, to a closed infusion set for administering an anticancer drug, which is configured so that an introduction needle and an infusion chamber are separated as independent elements and can be connected to each other in an openable manner, thereby ensuring safety without the risk of contamination, leakage, or infection of the anticancer drug that may occur during administration.

[0002] An IV set is a widely known medical device that can administer a prescribed amount of medication to a patient by drip.

[0003] This infusion set (1), as shown in an example in Fig. 1, typically includes an introduction needle (2), a drip chamber (3), a tube (4), a flow regulator (5), etc., and depending on the intended use, other materials such as a Y-connector, a male connector, a catheter connection, etc. can be combined in the middle or lower configuration.

[0004] The above introduction needle (2) is a part that is fitted into the rubber stopper of the infusion container in which the medicine is stored to discharge the medicine, and the drip chamber (3) is a part that is integrally provided at the bottom of the introduction needle to temporarily store the discharged medicine for a certain period of time.

[0005] In order to administer medication through this type of IV set, first, the prescribed medication is injected into the IV container where the IV is stored using a syringe in the dispensing room to prepare the medication to be administered, then the IV container is moved to the location where the medication is to be administered, and then the introduction needle (2) of the IV set is inserted into the rubber stopper of the IV container to connect the IV container and the IV set.

[0006] However, the following problems arise in the conventional medication process as described above.

[0007] To make a medication solution, the needle of the syringe is inserted directly into the rubber stopper of the IV container and the medication is injected into the IV container. During this process, there is a risk of being pricked by the needle or being exposed to the medication.

[0008] In particular, there is a problem that there is a risk of contamination or leakage of the drug solution during the time between the time of needle removal and the time of insertion of the injection needle.

[0009] That is, since the injection needle inserted from the rubber stopper of the IV container must be removed, and the IV container containing the medicine must be moved from the dispensing room to the administration location such as the patient room or treatment room, and then the introduction needle must be inserted into the IV container, there is an inevitable risk that during this process, external foreign substances such as bacteria may enter the IV container, contaminating the medicine in the IV container or leaking it to the outside, causing infection.

[0010] In particular, since this process is not carried out quickly and there are many cases where time is delayed, the possibility of danger is high, and in the case of drugs that require more care in handling, such as anticancer drugs, the risk is even greater.

[0011] The present invention is proposed to solve the above-mentioned conventional problems, and the purpose of the present invention is to provide a closed IV set for administering anticancer drugs, which can administer anticancer drugs more hygienically and safely by minimizing the risk of contamination, leakage, and infection during the process of preparing an anticancer drug solution in a dispensing room and connecting it to an IV set.

[0012] As a problem-solving means of the present invention to achieve the above-mentioned purpose,

[0013] A closed infusion set for administering an anticancer drug is disclosed, which comprises an introduction needle, a drip chamber, and a tube, and guides the administration of a drug solution stored in an infusion container to a patient, wherein the introduction needle and the drip chamber are configured separately from each other, a first connecting member is provided at the lower end of the introduction needle, and a second connecting member is provided at the upper end of the drip chamber that is detachably connected to the first connecting member.

[0014] Here, when the first connecting member and the second connecting member are connected to each other, the internal flow path can be opened, and when they are separated, the internal flow path can be closed.

[0015] According to the closed IV set for administering anticancer drugs according to the present invention,

[0016] In the process of preparing the anticancer drug solution and connecting it to the IV set, the sealed state of the IV container can be maintained, and since the insertion process of the introduction needle is performed before preparation, the possibility of contamination, leakage, or infection of the anticancer drug solution is minimized, so there is an advantage in that the anticancer drug can be administered more hygienically and safely.

[0017] In addition, it is added that, in addition to the effects specifically stated above, unique effects that can be easily derived and expected from the characteristic configuration of the present invention may also be included in the effects of the present invention.

[0018] Figure 1 is a drawing schematically illustrating the main components of a conventional sap set.

[0019] Figure 2 is a drawing schematically illustrating the main configuration of a closed sap set according to one embodiment of the present invention.

[0020] Figure 3 is a schematic diagram illustrating a closed IV set in which the introduction needle and the drip chamber are switched to a connected state in Figure 2.

[0021] Figure 4 is a drawing illustrating a process of inserting a needle into a sap container in a separated state.

[0022] Figure 5 is a drawing illustrating a process of connecting a drip chamber and a sap container with an introduction needle.

[0023] Hereinafter, a preferred embodiment of a closed IV set for administering an anticancer agent according to the present invention will be described in detail with reference to the attached drawings.

[0024] This embodiment is provided to more completely explain the present invention to a person having average knowledge in the art, and the shape, size, number, spacing between elements, etc. of elements in the attached drawings may be expressed in a reduced or exaggerated manner to emphasize a clearer explanation, and are not limited to the matters shown in the drawings unless specifically limited.

[0025] Additionally, in describing embodiments, when it is described that a component is “equipped with,” “formed with,” “installed with,” “connected with,” or “coupled with” another component, it should be understood that it may be directly equipped with, formed with, installed with, connected to, or coupled to the other component, but that other components may also be present in between.

[0026] Additionally, it should be understood that terms indicating directions such as front, back, left, right, up, down, etc. in the attached drawings and the description below are only used to describe the directions depicted and observed in the drawings, and that these terms may also change if the depicted and observed directions change.

[0027] In addition, in principle, when explaining an embodiment, if it is judged that the technical features of the present invention may be unnecessarily obscured because they are already obvious to a person skilled in the art, such as the function or composition of a related public notice, a detailed description thereof will be omitted.

[0028]

[0029] FIGS. 2 and 3 illustrate an example of a closed IV set for administering an anticancer drug according to one embodiment of the present invention.

[0030] As illustrated in the above drawings 2 and 3, a closed infusion set (100, hereinafter abbreviated as “infusion set”) for administering an anticancer agent according to one embodiment of the present invention may basically include an introduction needle (10), a drip chamber (20), a tube (30), a first connecting member (40), and a second connecting member (50).

[0031] In addition to the above-described components, other elements such as a flow controller and a catheter connection part may be included, but since these elements are known components included in a typical IV set and are unrelated to the features of the present invention, a description thereof will be omitted.

[0032] The above introduction needle (10) is an element that is inserted into the rubber stopper (210) of the intravenous solution container (200) in which the intravenous solution is stored and connected to the intravenous solution container (200), thereby discharging the intravenous solution from the intravenous solution container (200).

[0033] Here, the above-mentioned drug may be an anticancer drug in particular.

[0034] The above-mentioned drip chamber (20) is an element that temporarily stores the drug solution discharged through the introduction needle (10) for a certain period of time so that the drug solution can be administered in a drip manner.

[0035] The above tube (30) is an element that guides the transfer of the liquid as a tube that is connected to and extends from the lower end of the drip chamber (20), and other elements such as a flow controller can be arranged and configured in various ways along the transfer path of the tube (30) depending on the intended use.

[0036] The above-mentioned introduction needle (10), drip chamber (20), and tube (30) are also components included in a typical IV set, but in the case of this embodiment, the introduction needle (10) and drip chamber (20) have the characteristic of being configured separately from each other.

[0037] That is, while the conventional sap set is configured as an integrated structure in which the introduction needle is formed integrally in a form extending upward from the top of the drip chamber by a certain length, the present embodiment has the characteristic that the introduction needle (10) and the drip chamber (20) are separated from each other and each is configured as an independent element.

[0038] And, the introduction needle (10) and the drip chamber (20) configured separately as above may be provided with the first connecting member (40) and the second connecting member (50), respectively.

[0039] That is, the first connecting member (40) may be provided at the lower end of the introduction needle (10), and the second connecting mumble (50) may be provided at the upper end of the drip chamber (20).

[0040] To this end, a lower installation part (11) for fixing and installing the first connecting member (40) may be further formed at the lower end of the introduction needle (10), and an upper installation part (21) for fixing and installing the second connecting member (50) may be further formed at the upper end of the drip chamber (20).

[0041] The first connecting member (40) and the second connecting member (50) can be removably connected to each other.

[0042] That is, the first connecting member (40) and the second connecting member (50) are detachably connected to each other, so that the introduction needle (10) and the drip chamber (20), which are made up of separate and independent elements, can be selectively connected.

[0043] In addition, the first connecting member (40) and the second connecting member (50) may be configured to be connected to each other so that when the connection is made, the internal flow path is opened so that the drug can pass through the connected first connecting member (40) and second connecting member (50), and when the connection is released and separation is made, the internal flow path is closed so that the transfer of the drug is blocked.

[0044] That is, the first connecting member (40) and the second connecting member (50) have a configuration in which the internal flow paths are kept closed when they are separated from each other, but the internal flow paths are selectively opened to establish communication only when they are connected to each other.

[0045] Here, the first connecting member (40) and the second connecting member (50) are not limited to a special configuration, and as long as they can be detachably connected to each other and have a structure in which the flow path can be switched to open or close depending on the connection or separation state, various configurations disclosed in the past can be widely applied.

[0046]

[0047] The process of administering an anticancer drug using the present invention having the above-described configuration will be briefly described below with reference to FIGS. 4 and 5.

[0048] First, the anticancer solution to be administered is prepared in the dispensing room. As shown in FIG. 4, the introduction needle (10) with the first connecting member (40) fixedly mounted is inserted into the solution container (200) in which the solution is stored, thereby connecting the introduction needle (10) to the solution container (200).

[0049] At this time, the above-mentioned sap container (200) may be either a sap bag or a sap bottle.

[0050] Here, when inserting the introduction needle (10) toward the rubber stopper (210) of the infusion container (200), there may be a risk of a small amount of leakage if careless. However, when using the present invention, the introduction needle (10) is inserted before the preparation of the anticancer drug solution, so there is less risk of infection due to leakage.

[0051] That is, there is a risk of leakage during the process of inserting the introduction needle (10) into the rubber stopper (210) of the infusion container (200). The difference is that the object of leakage is the anticancer drug solution that has been manufactured in the conventional case, whereas in the present invention, it is the infusion solution before the anticancer drug is mixed.

[0052] In other words, when using a conventional IV set, the needle is inserted into the IV container containing the anticancer medication at the administration site after preparation is complete, so the anticancer medication may leak during this process, which poses a relative risk of infection, whereas when using the present invention, even if leakage occurs, it is not the anticancer medication but the IV solution from the pre-preparation stage that leaks, so the risk of infection, etc. can be relatively minimized compared to the conventional method.

[0053] After the introduction needle (10) is connected to the infusion container (200) as described above, a syringe (not shown in the drawing) containing the anticancer drug is connected to the introduction needle (10) to prepare an anticancer drug solution by mixing the prescribed anticancer drug with the infusion.

[0054] At this time, an additional connecting member identical to the second connecting member (50) of the present invention may be provided at the tip of the syringe, and when the additional connecting member provided in the syringe is connected to the first connecting member (40) of the introduction needle (10), the path is opened, and thus, the anticancer drug of the syringe can be injected into the infusion container (200), thereby preparing an anticancer drug solution.

[0055] And, when the preparation of the anticancer drug solution is completed as above, the syringe is separated from the introduction needle (10), and the intravenous solution container (200) containing the anticancer drug solution is moved to the injection site while the introduction needle (10) is still connected.

[0056] That is, the infusion container (200) containing the anticancer drug is moved from the preparation room to the administration site in the state in which the introduction needle (10) is connected. At this time, the introduction needle (10) is closed by the first connecting member (40) at the bottom, so the infusion container (200) to which the introduction needle (10) is connected can also be maintained in a sealed state.

[0057] Therefore, after the preparation of the anticancer medication is completed, the sealed state of the infusion container (200) is maintained until it is moved from the preparation room to the administration site and connected to the drip chamber (20), so that the risk of contamination, leakage, or infection of the anticancer medication can be minimized.

[0058] Next, after being moved to the injection site, as illustrated in FIG. 5, the first connecting member (40) of the introduction needle (10) and the second connecting member (50) of the drip chamber (20) are connected to the drip chamber (20) and the IV container (200) containing the anticancer drug solution.

[0059] Then, by opening the flow path according to the connection between the first connecting member (40) and the second connecting member (50), the anticancer drug solution can be safely supplied from the infusion container (200) to the drip chamber (20) without concern for contamination or leakage.

[0060] After the IV container (200) and the drip chamber (20) are connected in this way, the same process as using a normal IV set can be performed to administer the anticancer medication to the patient.

[0061]

[0062] As described above with respect to the present invention, according to the infusion set of the present invention, the sealed state of the infusion container can be maintained during the process of preparing an anticancer drug solution and connecting it to the infusion set, and since the insertion process of the introduction needle is performed at a stage prior to preparation, the risk of contamination, leakage, or infection of the anticancer drug solution is minimized, thereby providing improved safety.

[0063] The preferred embodiments of the present invention have been described in detail above, but the technical scope of the present invention is not limited to the above-described embodiments and the contents described in the drawings, and equivalent configurations modified or changed by a person having ordinary knowledge in the relevant technical field will not go beyond the scope of the technical idea of ​​the present invention.

Claims

1. In an infusion set (100) comprising a configuration including an introduction needle (10), a drip chamber (20), and a tube (30) to guide the administration of a drug solution stored in an infusion container to a patient, The above introduction needle (10) and the drip chamber (20) are configured separately from each other, A closed IV set for administering an anticancer drug, characterized in that a first connecting member (40) is provided at the lower end of the above-mentioned introduction needle (10), and a second connecting member (50) detachably connected to the first connecting member (40) is provided at the upper end of the above-mentioned drip chamber (20).

2. In paragraph 1, A closed IV set for administering an anticancer drug, characterized in that the first connecting member (40) and the second connecting member (50) are connected to each other so that the internal flow path is opened, and when separated, the internal flow path is closed.

Images